LipoScience, Inc. Release: Clinical Study Suggests LDL Particles Strongly Associated with Early-Stage Atherosclerosis
RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced publication of a clinical study in the current issue of Atherosclerosis suggesting that low density lipoprotein (LDL) particles may be a more accurate measure of early-stage (subclinical) atherosclerosis than LDL cholesterol among retired National Football League (NFL) players.